Pemetrexed + Cisplatin /Carboplatin

DRUG7 trials

Conditions

Advanced Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsCRC (Colorectal Cancer)CancerEGFR Exon 19 Deletion MutationEGFR Exon 21 L858R MutationEGFR Exon 21 MutationLocally Advanced or Metastatic NSCLC

Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

RecruitingNCT06835569

Alterome Therapeutics, Inc.Advanced Solid Tumors, Cancer, CRC (Colorectal Cancer) +2

Start: 2025-03-05End: 2029-08-01Target: 448Updated: 2026-06-10

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

Not yet recruitingNCT07699757

Haisco Pharmaceutical Group Co., Ltd.Advanced Solid Tumors, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)

Start: 2026-07-01End: 2029-11-01Target: 258Updated: 2026-07-14

Phase 2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

RecruitingNCT07365319

Eikon TherapeuticsNon Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

Start: 2026-06-15End: 2040-12-31Target: 750Updated: 2026-07-15

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Not yet recruitingNCT07709585

Guangzhou University of Traditional Chinese MedicineAdvanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 L858R Mutation +1

Start: 2026-07-05End: 2030-07-31Target: 124Updated: 2026-07-16

Phase 3

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

CompletedNCT05015608

Hutchison Medipharma LimitedNon-small Cell Lung Cancer

Start: 2021-11-22End: 2025-08-22Updated: 2026-05-27

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

NCT06110663

Jiangsu Hansoh Pharmaceutical Co., Ltd.Non-Small Cell Lung Cancer

Start: 2023-12-30End: 2025-02-28Target: 314Updated: 2023-11-01

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Not yet recruitingNCT07109531

Jiangsu Aosaikang Pharmaceutical Co., Ltd.Locally Advanced or Metastatic NSCLC

Start: 2025-08-31End: 2028-12-31Target: 286Updated: 2025-08-07

Related Papers

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

2026-01-13

A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025.

2025-10-31

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.

Journal of Clinical Oncology2025-06-047 citations